🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSTEP-HFpEF: semaglutide in heart failure with preserved EF — March 2026 Page 7

STEP-HFpEF: semaglutide in heart failure with preserved EF — March 2026

GenomicsKate Wed, Jun 4, 2025 at 7:34 PM 38 replies 1,967 viewsPage 7 of 8
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Nov 9, 2025 at 11:06 AM#31

A narrower follow-up, since the general answer is now clear:

How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?

1 1RickReta_CO
Reply Quote Save Share Report
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Nov 21, 2025 at 1:39 PM#32
GenomicsKate said:
Update since I posted: I held at 1.7mg for a further twelve weeks and lost another 4kg slowly, which settles it for me.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 72 pg/mL (normal, cardiac function preserved)
  • Lp(a): 32 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 152 to 97 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

50 0LeilaHI, marcus_mpls, DeniseRN_TPA and 47 others
Reply Quote Save Share Report
JakeSmashed95
Member
412
1,890
Aug 2024
Arkansas
Online
Dec 3, 2025 at 4:05 PM#33
GenomicsKate said:
Update since I posted: I held at 1.7mg for a further twelve weeks and lost another 4kg slowly, which settles it for me.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 4 of 5 diagnostic criteria to meeting ZERO after 9 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 48" → 36" ✅ Resolved
  2. Triglycerides: 238 → 113 ✅ Resolved
  3. HDL: 32 → 60 ✅ Resolved
  4. Blood pressure: 148/92 → 121/75 ✅ Resolved
  5. Fasting glucose: 118 → 84 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

49 24alex_tucson, kevin_tulsa, Dr.PainCLE and 46 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
Dec 15, 2025 at 6:24 PM#34
GenomicsKate said:
Update since I posted: I held at 1.7mg for a further twelve weeks and lost another 4kg slowly, which settles it for me.

Thank you for spelling out the reasoning rather than just the conclusion. I will report back once I have actually tried it.

48 23marco_milano, pam_columbus, nick_SD_fit and 45 others
Reply Quote Save Share Report
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Dec 27, 2025 at 8:36 PM#35

Adding the clinical framing, because it changes how the question reads.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.3 lbs/week average
Fasting glucose (finger stick): stable at 88 mg/dL
Blood pressure (home): 118/74 average
Resting heart rate: 68 bpm (down from 84)
Waist circumference: down 18 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

47 22BenResearch_OR, MikeKY_noInsulin, Dr.RaviCardio and 44 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register